Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-546-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.56 billion
Profitability
Miscellaneous
Employees23,300
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb declared a quarterly dividend on Thursday, June 13th. Investors of record on Friday, July 5th will be given a dividend of $0.41 per share on Thursday, August 1st. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date is Wednesday, July 3rd. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) announced its quarterly earnings results on Thursday, July, 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks' consensus estimate of $1.06 by $0.12. The biopharmaceutical company had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The company's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $1.01 EPS. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share guidance of $4.20-4.30 for the period, compared to the Thomson Reuters consensus estimate of $4.16.
What price target have analysts set for BMY?
16 brokerages have issued 12-month target prices for Bristol-Myers Squibb's stock. Their forecasts range from $46.36 to $66.00. On average, they expect Bristol-Myers Squibb's stock price to reach $56.0277 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb.
What is the consensus analysts' recommendation for Bristol-Myers Squibb?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.
Has Bristol-Myers Squibb been receiving favorable news coverage?
News articles about BMY stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Bristol-Myers Squibb.
Are investors shorting Bristol-Myers Squibb?
Bristol-Myers Squibb saw a increase in short interest in July. As of July 31st, there was short interest totalling 124,024,600 shares, an increase of 11.7% from the June 30th total of 111,017,000 shares. Based on an average trading volume of 13,480,000 shares, the short-interest ratio is presently 9.2 days. Approximately 7.6% of the shares of the stock are sold short. View Bristol-Myers Squibb's Current Options Chain.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Celgene (CELG), Bayer (BAYRY), Zoetis (ZTS) and Shire (SHPG).
What other stocks do shareholders of Bristol-Myers Squibb own?
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 54)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
- Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
- Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
- Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.20%), BlackRock Inc. (7.02%), Invesco Ltd. (1.47%), Northern Trust Corp (1.38%), Primecap Management Co. CA (1.33%) and Renaissance Technologies LLC (1.27%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Karen Murphy Santiago, Robert J Bertolini, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which institutional investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Jennison Associates LLC, Bank of Montreal Can, Point72 Asset Management L.P., Balyasny Asset Management LLC, Man Group plc, Public Employees Retirement Association of Colorado and APG Asset Management N.V.. View Insider Buying and Selling for Bristol-Myers Squibb.
Which institutional investors are buying Bristol-Myers Squibb stock?
BMY stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Baupost Group LLC MA, Renaissance Technologies LLC, BlackRock Inc., Janus Henderson Group PLC, Invesco Ltd., Price T Rowe Associates Inc. MD and Eaton Vance Management. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $46.98.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $76.85 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.View Additional Information About Bristol-Myers Squibb.
What is Bristol-Myers Squibb's official website?
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
